• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CPRX

    Catalyst Pharmaceuticals Inc.

    Subscribe to $CPRX
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

    IPO Year: 2006

    Exchange: NASDAQ

    Website: catalystpharma.com

    Peers

    $CBIO

    Recent Analyst Ratings for Catalyst Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    2/4/2025$28.00Outperform
    Robert W. Baird
    11/18/2024$35.00Overweight
    Stephens
    3/14/2024$27.00Buy
    Citigroup
    3/7/2024$23.00Buy
    BofA Securities
    12/21/2023$30.00Outperform
    Oppenheimer
    8/24/2022$10.00 → $15.50Buy → Neutral
    ROTH Capital
    2/8/2022$9.00 → $12.00Buy
    HC Wainwright & Co.
    See more ratings

    Catalyst Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

      Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

      5/7/25 4:14:54 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

      CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada. Presentation Details:Date: Wednesday, May 14, 2025Time: 8:00 am PTWebcast Link The webcast will be ava

      4/30/25 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

      CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:Interna

      4/22/25 8:02:59 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

      CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticosteroid treatment for Duchenne muscular dystrophy (DMD), for review. The submission has been granted Priority Review, expediting the regulatory process with the potential for marketing authorization befor

      4/8/25 8:06:35 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy

      Duchenne muscular dystrophy is a rare, debilitating and life-shortening neuromuscular disease1Upon approval, vamorolone would be the first and only treatment option indicated for patients diagnosed with Duchenne muscular dystrophy in CanadaThe Canadian regulatory submission of vamorolone follows approvals in the US in 2023, and the European Union in early 2024This New Drug Submission reflects Kye Pharmaceuticals' commitment to advancing treatments for rare diseases and serving the unmet needs of Canadian patientsMISSISSAUGA, ON, April 8, 2025 /PRNewswire/ - Kye Pharmaceuticals, Inc. ("Kye") announced today it has submitted a New Drug Submission (NDS) to Health Canada for the regulatory revie

      4/8/25 8:00:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

      CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 being held in Miami, Florida. Presentation DetailsDate: Tuesday, March 11, 2025Presentation: 1:00 PM ETWebcast Link The webcast will be available under t

      3/4/25 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb

      2/26/25 4:13:25 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

      CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025. Catalyst's management team will host a conference call and webcast on Thursday, February 27, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: February 27, 20

      2/12/25 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

      CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Mid-Cap Companies for the year 2025. Catalyst has ranked an impressive fifth out of 100 companies on the list. Last year Catalyst was ranked fourth in Forbes' list of America's Most Successful Small-Cap Companies, with this year's ranking recognizing the company's continued growth. The top 100 ranking is based on earnings growth, sales growth, return on equity and total stock return for the last five years, with more weight given to the latest year's data in the ranking. All data

      1/23/25 8:03:24 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

      CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome ("LEMS"). "We are pleased that our sub-licensee, DyDo, has launched FIRDAPSE in Japan. We believe in health equity, and this launch is a testament to our ongoing efforts

      1/21/25 8:19:06 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Med. & Reg. Officer Ingenito Gary exercised 225,000 shares at a strike of $2.24 and sold $4,894,610 worth of shares (225,000 units at $21.75) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      3/7/25 5:00:21 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Compliance/Legal Officer Elsbernd Brian exercised 62,525 shares at a strike of $2.24 and sold $1,446,933 worth of shares (62,975 units at $22.98) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      3/5/25 5:00:39 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Del Carmen Jeffrey sold $696,382 worth of shares (30,423 units at $22.89), closing all direct ownership in the company (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      3/5/25 5:00:24 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: New insider Russo Gregg claimed no ownership of stock in the company (SEC Form 3)

      3/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      2/28/25 5:40:23 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Russo Gregg claimed no ownership of stock in the company (SEC Form 3)

      3 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      2/26/25 5:00:18 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tierney David S converted options into 4,000 shares, increasing direct ownership by 1% to 355,620 units (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      2/19/25 5:00:31 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Denkhaus Donald A converted options into 4,000 shares, increasing direct ownership by 0.81% to 495,079 units (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      2/19/25 5:00:30 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Harper Molly converted options into 4,000 shares, increasing direct ownership by 146% to 6,746 units (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      2/19/25 5:00:27 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Daly Richard J converted options into 4,000 shares and covered exercise/tax liability with 1,574 shares, increasing direct ownership by 0.91% to 269,764 units (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      2/19/25 5:00:33 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Op. & Scientific Officer Miller Steve converted options into 13,667 shares, increasing direct ownership by 1% to 949,663 units (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      2/19/25 5:00:28 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Catalyst Pharma with a new price target

      Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00

      2/4/25 7:01:07 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Catalyst Pharma with a new price target

      Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00

      11/18/24 8:40:25 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Catalyst Pharma with a new price target

      Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00

      3/14/24 7:36:28 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Catalyst Pharma with a new price target

      BofA Securities initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $23.00

      3/7/24 8:09:47 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Catalyst Pharma with a new price target

      Oppenheimer initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $30.00

      12/21/23 6:58:11 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharma downgraded by ROTH Capital with a new price target

      ROTH Capital downgraded Catalyst Pharma from Buy to Neutral and set a new price target of $15.50 from $10.00 previously

      8/24/22 7:26:17 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Catalyst Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Catalyst Pharmaceuticals with a rating of Buy and set a new price target of $12.00 from $9.00 previously

      2/8/22 4:57:14 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on Catalyst Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of Catalyst Pharmaceuticals with a rating of Buy and set a new price target of $7.00 from $6.50 previously

      3/18/21 10:30:16 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

      8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      5/7/25 4:27:37 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Catalyst Pharmaceuticals Inc.

      10-Q - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      5/7/25 4:09:31 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Catalyst Pharmaceuticals Inc.

      SCHEDULE 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      4/28/25 12:32:55 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

      8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      4/9/25 8:55:12 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

      144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      3/5/25 4:09:16 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

      8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      2/26/25 4:37:46 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Catalyst Pharmaceuticals Inc.

      10-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      2/26/25 4:05:35 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Catalyst Pharmaceuticals Inc.

      SCHEDULE 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      2/13/25 8:57:09 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

      8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      1/24/25 4:30:14 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

      8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      1/21/25 4:30:15 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      11/14/24 9:55:56 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      10/18/24 3:31:27 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      10/17/24 12:14:52 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      2/13/24 5:00:59 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      2/12/24 5:31:52 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      1/25/24 10:09:21 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      1/22/24 3:52:12 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      2/14/23 12:27:02 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      2/10/23 9:28:55 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Catalyst Pharmaceuticals Inc.

      SC 13G - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      2/9/23 11:12:45 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

      Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

      5/7/25 4:14:54 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

      CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:Interna

      4/22/25 8:02:59 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb

      2/26/25 4:13:25 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

      CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025. Catalyst's management team will host a conference call and webcast on Thursday, February 27, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: February 27, 20

      2/12/25 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update

      Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance Highlights Operational Excellence and Strong Commercial Execution FIRDAPSE® Q3 2024 Net Product Revenues of $79.3 Million, Representing a 19.7% YoY Increase AGAMREE® Q3 2024 Net Product Revenues of $15.0 Million, Demonstrating Early U.S. Launch Success FYCOMPA® Q3 2024 Net Product Revenues of $32.1 Million Q3 2024 GAAP Net Income of $43.9 Million, $0.35 Per Share Diluted Q3 2024 Non-GAAP Net Income of $71.1 Million, $0.57 Per Share Diluted Updating 2024 Full Year Total Revenue Guidance to Be

      11/6/24 4:12:24 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

      CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2024 financial results after the market close on Wednesday, November 6, 2024. Catalyst's management team will host a conference call and webcast on Thursday, November 7, 2024, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details  Date:November 7, 2024Time:8:30 AM ET

      10/22/24 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update

      Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers of CHF 14.1 million (H1-2023: CHF 3.9 million)Operating result of CHF -17.7 million (H1-2023: CHF -20.3 million) and net result of CHF -15.3 million (H1-2023: CHF -23.3 million)AGAMREE® (vamorolone) launched in Germany and Austria as first European markets; North America partner has launched in the U.S.Approval of AGAMREE in the UK for the treatment of Duchenne muscular dystrophy (DMD); new drug application (NDA) in DMD under regulatory priority review in China Cash and cash

      9/12/24 1:00:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update

      Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million, Representing a 23.2% YoY Increase FIRDAPSE® Q2 2024 Net Product Revenues of $77.4 Million, Reflecting Strong Organic 19.2% YoY Growth AGAMREE® Q2 2024 Net Product Revenues of $8.7 Million Demonstrates a Strong Start to U.S. Commercialization FYCOMPA® Q2 2024 Net Product Revenues of $36.5 Million, Representing a 5.7% YoY Increase Q2 2024 GAAP Net Income of $40.8 Million, $0.33 Per Share Diluted Q2 2024 Non-GAAP Net Income of $69.6 Million, $0.56 Per Share Diluted Reaffirming 2024 Total Revenue G

      8/7/24 4:11:34 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

      CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2024 financial results after the market close on Wednesday, August 7, 2024. Catalyst's management team will host a conference call and webcast on Thursday, August 8, 2024, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details Date:Time:US/Canada Dial-in Number:Inte

      7/22/24 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

      Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures:        Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million)        Net result of CHF 54.8 million (2022: CHF -71.1 million)         Cash flow from operating activities of CHF 47.6 million (2022: CHF -29.8 million)Regulatory approvals in key territories – AGAMREE® (vamorolone) approved for Duchenne muscular dystrophy (DMD) treatm

      4/25/24 1:00:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

      CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene. "At Catalyst, our commitment to the community is unwavering, particularly in times of crisis," said Richard J. Daly, President and CEO of Catalyst. "We extend our heartfelt sympathies to those affected by Hurricane Helene and are honored to contribute to the

      10/8/24 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

      Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024. Mr. Kalb will report directly to the Company's Chief Executive Officer and will serve as a member of the Company's executive leadership team. Mr. Kalb's distinguished career in

      12/4/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

      CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Richard J. Daly as its new Chief Executive Officer ("CEO") effective January 1, 2024. Mr. Daly is a seasoned pharmaceutical executive bringing more than three decades of experience to Catalyst. In order to facilitate an orderly transition, Patrick J. McEnany, Founder, Chairman, and CEO, will retire from the CEO position effective December 31, 2023, and at that time will contin

      10/19/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End

      Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search CORAL GABLES, Fla., July 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced that Patrick J. McEnany, Catalyst's Co-Founder, Chairman, and Chief Executive Officer ("CEO") has informed the Board of Directors ("Board") of his intention to retire from his position as CEO by the end of 2023. Mr. McEnany remains the Company's largest individual stockholder and will continue to serve as CEO until his replacement is in place. There

      7/25/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

      CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Ms. Tamar Thompson to the Company's Board of Directors ("Board"), effective on May 25, 2023. "We are extremely pleased to welcome Tamar to our Board as she brings a wealth of experience to our team across several therapeutic categories, including rare diseases, coupled with extensive health policy and government affairs acumen," said Patrick J. McEnany, Chairman and CEO of Cat

      5/30/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

      SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin

      1/17/22 8:50:00 AM ET
      $BYSI
      $CPRX
      $OPNT
      $PALI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations

      CORAL GABLES, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Mary Coleman has been appointed to the newly created position of Vice President, Head of Investor Relations. This position will report to the Chief Executive Officer of Catalyst. "We are delighted to welcome Ms. Coleman to the Catalyst team. Her extensive investor relations experience in the pharmaceutical industry and insights make her uniquely qualified to support our inves

      8/16/21 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer

      CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Dr. Preethi Sundaram as Chief Product Development Officer. This position will report to the Chief Executive Officer. "On behalf of Catalyst, I am very pleased to welcome Dr. Sundaram to the Catalyst senior leadership team. Dr. Sundaram's extensive product development and portfolio building experience uniquely qualifies her for this newly-created position, as s

      7/6/21 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors

      CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Molly Harper to the Company's Board of Directors. "On behalf of the Board of Directors, I am very pleased to welcome Ms. Harper to the Catalyst board. Ms. Harper is a highly accomplished life-science executive with broad background in rare disease drug development, commercialization and strategic planning across a diverse range of therapeutic areas. Her experi

      6/29/21 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update

      Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms Firdapse® 2020 Net Revenues Estimate of approximately $118 Million; about 16% Increase From 2019Ended 2020 with Estimated $140 Million in Cash and InvestmentsCompany Highlights Current Product Development Programs CORAL GABLES, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced an expansion in its strategic priorities relat

      1/6/21 8:07:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care